拜耳“走进西部”,助力中国医疗卫生基础建设

2016-08-30 佚名 拜耳

“走进西部”卫生人才项目是国家卫生和计划生育委员会与拜耳联合开展的战略合作伙伴计划。项目实施九年来,已在全国26个省份完成208期培训,培养卫生人才逾3万人次。

昆明2016年8月29日电 /美通社/ -- 2016年8月25日至26日,由国家卫生和计划生育委员会、云南省卫生和计划生育委员会主办,云南省医院协会、昆明医科大学承办,国家卫生和计划生育委员会医院管理研究所协办,拜耳支持的走进西部卫生人才培训项目云南省县级医院管理干部培训班及骨干医师培训班在昆明拉开帷幕。“走进西部”卫生人才项目是国家卫生和计划生育委员会与拜耳联合开展的战略合作伙伴计划。项目实施九年来,已在全国26个省份完成208期培训,培养卫生人才逾3万人次。

支持基础医疗体系建设,助力分级诊疗制度实施

近年来随着医疗改革的持续深化,建立分级诊疗制度的重要性日益凸显。2015年,国务院办公厅《关于推进分级诊疗制度建设的指导意见》明确提出以强基层为重点完善分级诊疗服务体系,大力提高基层医疗卫生服务能力,全面提升县级公立医院综合能力。拜耳多年来致力于帮助中国改善基层医疗水平,提升医疗系统的效率和质量,特别是在支持分级诊疗制度的建立中扮演了先锋角色。早在2007年,拜耳与国家卫生和计划生育委员会(原卫生部)共同发起了“走进西部”卫生人才培训项目,计划在十年内为中西部省(区、市)培养县级医院骨干医师和管理干部。

与我国其他省份相比,中西部地区仍处于发展的初级阶段,医疗卫生水平尚存较大的差距,医疗卫生人才的培训和建设是解困的关键。“走进西部”卫生人才培训项目,以创新形式,持之以恒地运用各方优势共同营造一个更广阔的培训服务平台,满足更多渴求新知识、新技术的中西部基层卫生人才的需求,加快提升他们的医疗水平和管理能力。

云南省卫生和计划生育委员会副主任张宽寿表示:“目前正值国家全面推开县级公立医院改革,‘走进西部’卫生人才培训项目的实施具有十分重要的意义。在国家卫生和计划生育委员会与拜耳的大力支持下,云南省于2008年启动该项目,不断提高医院的管理能力和服务能力,从而满足全省广大人民群众日益增长的医疗卫生服务需求。”

可持续发展的基层卫生人才培养项目

据统计,中国医疗卫生资源配置不均衡,80%在城市,20%在农村。一方面基层缺乏高水平医疗卫生人才队伍;另一方面,基层医师毕业后缺乏继续教育的机会,医师队伍很难满足城乡居民日益增长的医疗卫生服务需求。与此同时,推进分级诊疗制度的建立使得加强基层医疗卫生人才队伍建设迫在眉睫。“走进西部”卫生人才培训项目分设县级医院管理干部培训班和县级医院骨干医师培训班,以提高县级医院医生对常见疾病的诊疗能力以及医院管理人员的管理水平。项目课程的设计切实结合地方卫生工作重点,培训授课范围广,云集国内各领域知名专家。以云南省医师班为例,课程领域不仅涵盖内科、外科、妇产科、儿科、等县级医院薄弱专科,还率先探索性地开展影像、检验、口腔、药理等专题培训,理论与实践相结合,使学员收获良多。

云南省是项目中开班期数最多、培训学员人数最多的省份之一,培训项目在云南历经八年,惠及当地卫生人才3000余人次。云南省医院协会会长杜克琳介绍说:“‘走进西部’项目已经成为全国知名的卫生人才培养项目,深受广大卫生工作者欢迎。培训课程精心设计,紧密结合地方需求,既反映了不同时段国内外最前沿的医疗、医院管理的理论和知识,同时与医改和医疗技术相结合,具有很强的实用性。”

2016年,“走进西部”卫生人才培训项目将继续积极配合分级诊疗相关政策,以加强县级医院医师专业技术能力为目的,把侧重点放在高血压糖尿病等慢性疾病的管理上,进一步提升医师的诊疗水平,从而提升县级医院医疗服务水平,助力医改。

拜耳处方药事业部中国及亚太区执行副总裁兼中国区总裁江维先生表示:“拜耳全力支持中国政府建立覆盖城乡居民的基本医疗卫生体制。我们将利用自身专长和能力,帮助中国加强基层和欠发达地区医疗卫生机构的专业能力和服务能力,为打造健康中国贡献力量。”

拜耳 -- 科技创造美好生活

拜耳作为一家跨国企业,其在生命科学领域的核心竞争力包括医药保健和植保。公司产品和服务致力于造福人民,提高人们的生活质量。同时,拜耳还通过科技创新、业务增长和高效的盈利模式来创造价值。拜耳集团致力于可持续发展,认可并接受其作为企业公民的社会责任和道德责任。2015年财政年度,拜耳的员工人数为117,000名,销售额为463亿欧元,资本支出为26亿欧元,研究开发投入为43亿欧元。这些数据包括高科技聚合物材料业务的数据,该业务已于2015年10月6日以Covestro(中文译名:科思创)作为商号成为独立的公司上市。更多信息请见www.bayer.com。

前瞻性声明

本新闻稿包括拜耳集团管理层基于当前设想和预测所作的前瞻性声明。各种已知和未知的风险、不确定性和其它因素均可能导致公司未来的实际运营结果、财务状况、发展或业绩与上述前瞻性表述中所作出的估计产生重大差异。这些因素包括在拜耳官方网站http://www.bayer.com/上公开的拜耳各项报告。本公司没有责任更新这些前瞻性声明或使其符合未来发生的事件或发展。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
    2016-09-01 ying_wu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
    2016-08-30 chenchuny

    是否能切实有效有待观察

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
    2016-08-30 刘煜

    走近西部,送医下乡。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
    2016-08-30 doctorJiangchao

    继续学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1722729, encodeId=6c911e22729f0, content=<a href='/topic/show?id=95a821e42a1' target=_blank style='color:#2F92EE;'>#中国医疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21742, encryptionId=95a821e42a1, topicName=中国医疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c62f33313955, createdName=charleshjw, createdTime=Fri Oct 14 22:18:00 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318447, encodeId=4473131844ede, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530888, encodeId=def6153088899, content=<a href='/topic/show?id=4cd534866c9' target=_blank style='color:#2F92EE;'>#医疗卫生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34866, encryptionId=4cd534866c9, topicName=医疗卫生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ee212178304, createdName=wangtianj2011@, createdTime=Thu Sep 01 00:18:00 CST 2016, time=2016-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107638, encodeId=e13410e638ff, content=是否能切实有效有待观察, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=014e108570, createdName=chenchuny, createdTime=Tue Aug 30 18:06:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107365, encodeId=8fbe10e365e5, content=走近西部,送医下乡。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Tue Aug 30 11:10:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107280, encodeId=c82a10e28034, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107282, encodeId=d09f10e282fc, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Aug 30 10:40:00 CST 2016, time=2016-08-30, status=1, ipAttribution=)]
    2016-08-30 doctorJiangchao

    继续关注

    0

相关资讯

拜耳A型血友病药物Kovaltry获FDA批准

近日,美国FDA批准拜耳A型血友病药物Kovaltry上市,用于儿童和成人A型血友病患者。Kovaltry是一种是未经修饰的重组因子VIII化合物。 FDA此次积极监管意见主要依据一项名为LEOPOLD的长期临床试验研究,主要考察Kovaltry常规预防给药在成人、青少年和儿童A型血友病患者中的药动学、安全性和疗效,以及对围手术期出血护理的影响。FDA推荐Kovaltry在青少年和成人中剂量

Dimension与拜耳签订2亿5千万美元合作协议

在过去7个月中,Dimension Therapeutics公司作出一系列举措不断推进基因治疗疗法。上周五Dimension公司又有新动作,公司与拜耳公司签订了一项总价值约2亿5千万美元的协议。根据这一协议,拜耳公司将资助Dimension公司开发的治疗A型血友病的所有临床前研究以及随后的前期临床研究。一旦获得成功,拜耳公司将负责最后的临床上三期研究,一旦成功,拜耳公司将获得这种疗法的全球商业权

消息!拜耳抗癌药Stivarga肝细胞癌III期临床大获成功

  拜耳抗癌药Stivarga近日在关键III期临床试验中获得积极数据,有望将肝细胞癌列入适应症名单。Stivarga是一种口服的多激酶抑制剂,能够抑制肿瘤发生发展中VEGFR 1-3、KIT、RET、PDGFR及FGFR等多种重要激酶的活性,目前已经在多个肿瘤中获批。 这项名为RESORCE的III期临床试验数据表明,Stivarga (regorafenib)能够显着

默沙东宣布以142亿美元将健康消费品业务出售给拜耳

默沙东公司(纽交所证券代码MRK,在美国和加拿大称为默克)今天宣布与拜耳达成最终协议,以142亿美元的价格将健康消费品业务出售给拜耳。根据协议条款,拜耳将收购默沙东的非处方药(OTC)业务,包括开瑞坦和Afrin的全球商标和处方权。 同时,默沙东宣布在全球范围内与拜耳进行临床开发合作,共同研发和销售可溶性鸟苷酸环化酶(sGC)调节剂。合作范围包括拜耳的同类首创药物Adempas?(riocigua

拜耳Gadavist(加乐显)——FDA批准用于升主动脉MRA的造影剂

德国制药巨头拜耳(Bayer)开发的造影剂Gadavist(商品名:加乐显,通用名:gadobutrol,钆布醇)注射液近日获FDA批准用于磁共振血管造影(MRA)诊断,评估成人及儿科患者(包括新生儿)中已知或可疑的升主动脉或肾动脉疾病。此次批准,使Gadavist成为美国市场首个可用于升主动脉MRA的造影剂。 作为全球MRI造影剂市场的领导者,此次批准,也是拜耳Gadavist在过去2年中

后生可畏,拜耳眼科药物Eylea第4个适应症获欧盟批准

拜耳(Bayer)及合作伙伴再生元(Regeneron)近日宣布,眼科药物(aflibercept,阿柏西普注射液)在欧盟收获第4个适应症。欧盟委员会(EC)已批准Eylea用于视网膜静脉阻塞继发黄斑水肿(RVO-ME)的治疗,包括视网膜分支静脉阻塞继发黄斑水肿(BRVO-ME)及先前已获批的视网膜中央静脉阻塞继发黄斑水肿(CRVO-ME)。建议的治疗方法为:起始治疗时每周注射一次直至达到最大